Treatment of cystic fibrosis - a difficult task, requiring large material costs related to an incurable disease and is an important medical and social problem of child health. This dramatically reduces the pathology of life in these patients. The average life expectancy of patients with cystic fibrosis is 29 years. To date, the only Pulmozim biotech drug, created specifically for the treatment of cystic fibrosis. Application Pulmozima significantly reduces the number of complications of cystic fibrosis.
Given the social importance of the drug dornase alfa (Pulmozim solution for inhalation 2.5 mg), as well as taking into account the situation to ensure that these drugs children with cystic fibrosis, we intend to provide charitable assistance and to donate to the clinic RK drug Pulmozim p / p for ING. 2.5 mg in 4020 the number of vials. Previously, we had already been transferred to 240 vials in 4 regions of Republic on agreement with the "Committee control of medical and pharmaceutical activity" MZRK (letter of 05/26/2011, the № 15-3/8902011).
25 of July at 11.00 a.m. in Almaty KPC "Medservice Plus" LLP was made a donation dornase alfa (Pulmozim, solution for inhalation 2.5 mg) on amount of 4020 vials of representative "of the Committee monitoring the medical and pharmaceutical activity" MZRK represented by Vice-President Pak Yong-Larisa Boevne. The mdicine transferred to the medical institutions of the Republic, according to the distribution list MZRK, for distribution by region of Kazakhstan, totaling 23 456 412.00 tenge.